Effects of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT

doi:10.1016/0378-5173(86)90050-5

International Journal of Pharmaceutics

Volume 33, Issues 1–3, November 1986, Pages 165-172

https://doi.org/10.1016/0378-5173(86)90050-5 Get rights and content

Abstract

The effect of lipid vehicle volume and lipid class on the intestinal lymphatic transport of DDT (1,1-bis(p-chlorophenyl)-2,2,2-tri- chlorethane;p,p-DDT) has been investigated in anesthetized rats. Two milligrams of DDT, dissolved in either 50 μ1 or 200 μl of lipid, was infused intraduodenally. The lymphatic transport of DDT was followed by HPLC analysis of hourly lymph samples collected from the intestinal mesenteric lymph duct. Three types of lipid vehicles were utilized in this study, peanut oil (triglyceride), oleic acid (fatty acid) and a 2:1 mixture of oleic acid-monoolein, which represents the lumenal digestion products of a triglyceride. There were major and significant differences in the kinetics of lymphatic transport of DDT and in the cumulative amount of DDT transported when administered in the different lipid vehicles. Cumulative intestinal lymphatic transport of DDT was greatest when administered in either oleic acid or the 2:1 mixture of oleic acid-monoolein. Peanut oil was the least effective lipid vehicle with respect to the lymphatic transport of DDT. A comparison of the lymphatic transport of DDT when administered in the two dose volumes revealed no significant difference in the cumulative transport of DDT within a particular lipid class (triglyceride, fatty acid or oleic acid-monoolein).

References (21)

R. Blomhoff et al.
Lymphatic absorption and transport of retinol and vitamin D-3 from rat intestine
Biochim. Biophys. Acta.
(1984)
W.N.A. Charman et al.
An experimental system designed to study the in situ intestinal lymphatic transport of lipophilic drugs in anesthetized rats
Int. J. Pharm.
(1986)
J.M. Laher et al.
Similar bioavailability and lymphatic transport of benzo(a)pyrene when administered to rats in different amounts of dietary fat
J. Lipid Res.
(1984)
T. Noguchi et al.
The effect of drug lipophilicity and lipid vehicles on the lymphatic absorption of various testosterone esters
Int. J. Pharm.
(1985)
T. Noguchi et al.
Lymphatic appearance of DDT in thoracic or mesenteric lymph duct cannulated rats
Int. J. Pharm.
(1985)
R.F. Ockner et al.
Differences in the intestinal absorption of saturated and unsaturated long chain fatty acids
Gastroenterology
(1972)
J.S. Patton et al.
Solubility of fatty acids and other hydrophobic molecules in liquid trioleoylglycerol
J. Lipid Res.
(1984)
R.D. Vetter et al.
Coassimilation of dietary fat and benzo(a)pyrene in the small intestine: an adsorption model using killifish
J. Lipid Res.
(1985)
J.L. Bollman et al.
Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat
J. Lab. Clin. Med.
(1948)
B. Borgstrom et al.
Studies of intestinal digestion and absorption in the human
J. Clin. Invest.
(1957)

There are more references available in the full text version of this article.

Cited by (73)

Structured edible lipid-based particle systems for oral drug-delivery
2022, Biotechnology Advances
Oral administration is the most popular and patient-compliant route for drug delivery, though it raises great challenges due to the involvement of the gastro-intestine (GI) system and the drug bioavailability. Drug bioavailability is directly related to its ability to dissolve, transport and/or absorb through the physiological environment. A great number of drugs are characterized with low water solubility due to their hydrophobic nature, thus limiting their oral bioavailability and clinical use. Therefore, new strategies aiming to provide a protective shell through the GI system and improve drug solubility and permeability in the intestine were developed to overcome this limitation. Lipid-based systems have been proposed as good candidates for such a task owing to their hydrophobic nature which allows high drug loading, drug micellization ability during intestinal digestion due to the lipid content, and the vehicle physical protective environment. The use of edible lipids with high biocompatibility paves the bench-to-bedside translation. Four main types of structured lipid-based drug delivery systems differing in the physical state of the lipid phase have been described in the literature, namely emulsions, solid lipid nanoparticles, nanostructured lipid carriers, and oleogel-based particles. The current review provides a comprehensive overview of the different structured edible lipid-based oral delivery systems investigated up to date and emphasizes the contribution of each system component to the delivery performance, and the oral delivery path of lipids.
Natural sesame oil is superior to pre-digested lipid formulations and purified triglycerides in promoting the intestinal lymphatic transport and systemic bioavailability of cannabidiol
2021, European Journal of Pharmaceutics and Biopharmaceutics
Citation Excerpt :
It has been reported previously that lipid-based formulations can increase the intraluminal solubility of lipophilic drugs and enhance the drug absorption. Moreover, oral administration of highly lipophilic drugs in lipid-based formulations containing long-chain triglycerides or long-chain fatty acids results in intestinal lymphatic transport and therefore avoids hepatic first-pass metabolism [9,35]. CBD is a highly lipophilic drug which has high affinity to both rat and human chylomicrons and extensive intestinal lymphatic transport when administered orally with a long-chain triglyceride vehicle (sesame oil) [16,17].
Lipid-based formulations play a significant role in oral delivery of lipophilic drugs. Previous studies have shown that natural sesame oil promotes the intestinal lymphatic transport and oral bioavailability of the highly lipophilic drug cannabidiol (CBD). However, both lymphatic transport and systemic bioavailability were also associated with considerable variability. The aim of this study was to test the hypothesis that pre-digested lipid formulations (oleic acid, linoleic acid, oleic acid with 2-oleoylglycerol, oleic acid with 2-oleoylglycerol and oleic acid with glycerol) could reduce variability and increase the extent of the intestinal lymphatic transport and oral bioavailability of CBD. The in vivo studies in rats showed that pre-digested or purified triglyceride did not improve the lymphatic transport and bioavailability of CBD in comparison to sesame oil. Moreover, the results suggest that both the absorption of lipids and the absorption of co-administered CBD were more efficient following administration of natural sesame oil vehicle compared with pre-digested lipids or purified trioleate. Although multiple small molecule constituents and unique fatty acid compositions could potentially contribute to a better performance of sesame oil in oral absorption of lipids or CBD, further investigation will be needed to identify the mechanisms involved.
A Retrospective Biopharmaceutical Analysis of >800 Approved Oral Drug Products: Are Drug Properties of Solid Dispersions and Lipid-Based Formulations Distinctive?
2020, Journal of Pharmaceutical Sciences
Citation Excerpt :
The “spring and parachute” analogy applies here to the generation and prolongation of supersaturation where the “spring” involves the self-emulsifying properties of the LBF, incorporating the solubilised active substance 33, while “parachute” refers to formulation additives which increase stability, reducing drug precipitation in vivo34 (Fig. 2). LBFs are also biopharmaceutically advantageous regarding impact on intestinal permeability,35 metabolism36 and lymphatic transport.37,38 Additionally, from a pharmaceutical manufacture standpoint, once acceptable manufacturing equipment is in place, large scale manufacture of LBFs is relatively low risk and less technologically demanding which can usually be completed on a smaller scale than other delivery technologies.15,39
Increasing numbers of poorly water soluble drugs in development has intensified need for bio-enabling formulations including Lipid-Based Formulations (LBF) and Solid Dispersions (SD). Resultantly, a data-driven approach is required to increase formulation development efficiency. This review provides a retrospective analysis of molecular and biopharmaceutical properties of drugs commercialised as LBFs or SDs. A comprehensive stepwise statistical analysis of LBF and SD drug properties was conducted and compared to drugs not commercialised via either technology (Others), aiming to identify key predictors of successful formulation development. This review demonstrates LBF and SD drugs differ significantly in molecular weight, polar surface area, rotatable bonds and hydrogen bond acceptor count. Meanwhile, LBF and SD drugs display significantly different aqueous solubility, lipophilicity, size, molecular flexibility, hydrogen bonding capacity and rule-of-5 violations versus Others. LBF and SDs were 3 and 5 times more likely to display >1 rule-of-5 violation versus Others, over 55% of LBF drugs exceeded the reported melting point guide of <150 °C, while 24% of SD drugs contained >10 Hydrogen Bond Acceptors. Overall, by focusing on successfully commercialised drugs, this review provides improved understanding of links between drug properties and successful SD/LBF approaches, providing a framework for guiding pharmaceutical development on formulation approaches.
Differential lymphatic versus portal vein uptake of the synthetic pyrethroids deltamethrin and cis-permethrin in rats
2020, Toxicology
The objective of this study was to obtain data on pathways of absorption of the synthetic pyrethroids deltamethrin (DLM) and cis-permethrin (CPM) following oral administration to rats. Adult male Sprague-Dawley rats with cannulated mesenteric lymph ducts and hepatic portal veins were given single doses of either 5 mg/kg DLM or 60 mg/kg CPM via the duodenum and lymph and portal blood samples collected for up to 300 min. The pyrethroid dosing vehicles (5 mL/kg body weight) were either corn oil or glycerol formal. Levels of DLM and CPM in lymph and portal blood samples were determined by high-performance liquid chromatography-mass spectrometry-mass spectrometry. Over the time period studied, levels of both DLM and CPM following administration in either corn oil or glycerol formal were greater in lymph than in portal blood. Lymphatic uptake of both DLM and CPM was enhanced following dosing in glycerol formal than in corn oil. The results of this study suggest that after oral administration to rats, these two pyrethroids are predominantly absorbed via the lymphatic system rather than via portal blood. The data obtained in this study thus support a recently developed physiologically-based pharmacokinetic (PBPK) model to evaluate age-related differences in pyrethroid pharmacokinetics in the rat, where it was assumed that absorption of pyrethroids was predominantly via lymphatic uptake.
Evaluating hexabromocyclododecane (HBCD) toxicokinetics in humans and rodents by physiologically based pharmacokinetic modeling
2019, Food and Chemical Toxicology
Hexabromocyclododecane (HBCD) is a flame retardant largely found in textiles, electrical equipment and building materials. The potential exposure associated with adverse effects described in animals make HBCD a substance of interest. To better characterize the risk in humans, it is important to understand the dose-response relationship using available data concerning the exposure and toxicity of environmental contaminants such as HBCD. For this reason, a physiologically-based pharmacokinetic (PBPK) model was developed to describe the disposition of α-HBCD after a single oral administration. The results showed that the model can appropriately predict blood and tissue concentration in rodents. The model described that lipoproteins play a key role in the distribution of α-HBCD in the body even though its lipophilic nature would suggest preferential storage in adipose tissue. The model was also adapted to humans to predict plasma exposure to α-HBCD and showed reasonable estimates when compared against estimated diet levels and biomonitoring measures. As part of a larger study on integrating new toxicity data for human health risk assessment, the present PBPK model will serve as a supporting tool to help extrapolate and interpret in vitro and in vivo kinetics of flame retardants such as HBCD.
Promoting intestinal lymphatic transport targets a liver-X receptor (LXR) agonist (WAY-252,623) to lymphocytes and enhances immunomodulation
2019, Journal of Controlled Release
Citation Excerpt :
WAY-252,623 is a highly lipophilic drug candidate with physicochemical properties that are consistent with the potential to be transported from the intestine via the lymph following oral delivery. Charman and Stella initially proposed that intestinal lymphatic transport following oral delivery is likely to be substantial for highly lipophilic drugs (Log D > 5, lipid solubility >50 mg/mL) that associate with intestinal lipoproteins [34]. This suggestion was made based on the realisation that the flow rate of blood through the intestinal blood capillaries and portal vein is substantially higher (~500-fold) than the flow rate of lymph through the intestinal lymphatics, and that 1% of lymph fluid consists of lipid.
Lymphocytes play a central role in the pathology of a range of chronic conditions such as autoimmune disease, transplant rejection, leukemia, lymphoma HIV/AIDs and cardiometabolic diseases such as atherosclerosis. Current treatments for lymphocyte-associated conditions are incompletely effective and/or complicated by a range of off-target toxicities. One major challenge is poor drug access to lymphocytes via the systemic blood and this may be attributed, at least in part, to the fact that lymphocytes are concentrated within lymph fluid and lymphoid tissues, particularly in gut-associated lymphatics. Here we demonstrate that promoting drug uptake into the intestinal lymphatics with a long chain fatty acid, thereby increasing lymphocyte access, enhances the pharmacodynamic effect of a highly lipophilic liver X receptor (LXR) agonist, WAY-252623, that has been suggested as a potential treatment for atherosclerosis. This has been exemplified by: (1) increased mRNA expression of key markers of LXR activation (ABCA1) and regulatory T cells (Foxp3) in local lymphatic lymphocytes and (2) enhanced numbers of CD4⁺CD25⁺Foxp3⁺ regulatory T cells in the systemic circulation, after administration of a 5-fold lower dose with a lymph directing lipid formulation when compared with a non-lipid containing formulation. These data suggest that combining lipophilic, lymphotropic drug candidates such as WAY-252,623, with lymph-directing long chain lipid based formulations can enhance drug targeting to, and activity on, lymphocytes in lymph and that this effect persists through to the systemic circulation. This presents a promising approach to achieve more selective and effective therapeutic outcomes for the treatment of lymphocyte associated diseases.

View all citing articles on Scopus

^∗: Present address: Sterling-Winthrop Research Institute, Rensselaer, NY 12144, U.S.A.

View full text

Effects of lipid class and lipid vehicle volume on the intestinal lymphatic transport of DDT

Abstract

Biochim. Biophys. Acta.

Int. J. Pharm.

J. Lipid Res.

Int. J. Pharm.

Int. J. Pharm.

Gastroenterology

J. Lipid Res.

J. Lipid Res.

Techniques for the collection of lymph from the liver, small intestine, or thoracic duct of the rat

J. Lab. Clin. Med.

Studies of intestinal digestion and absorption in the human

J. Clin. Invest.